Should You Buy or Hold Johnson & Johnson (NYSE:JNJ) Stock at $172?

Johnson & Johnson (NYSE:JNJ): A Comprehensive Review of Key Performance Factors and Growth Potential

When evaluating Johnson & Johnson (NYSE:JNJ), the pharmaceutical and medical device giant, several aspects need to be considered in understanding its long-term viability. As one of the largest and most diversified healthcare companies, JNJ’s financials, drug portfolio, and growth strategies demand a deeper dive, especially in comparison to competitors like Pfizer (NYSE:PFE). The stock's current price performance, revenue growth, and strategic acquisitions all play significant roles in shaping its future prospects.

Financial Performance and Revenue Growth

In the most recent quarter, Johnson & Johnson posted impressive revenue figures of $22.5 billion, up 5.23% year-over-year and a slight 0.22% quarter-over-quarter increase. While these figures are solid, they fall behind competitors in the healthcare space, such as Pfizer which reported revenue of $17.76 billion, reflecting a 24.9% year-over-year growth. Notably, J&J’s P/S ratio stands at 4.47x, which is 27.9% higher than the sector median but 3.71% lower than its 5-year average. This indicates a relatively higher market valuation compared to its peers, making JNJ a more expensive play at current levels.

Debt and Financial Stability

Looking at the balance sheet, J&J’s net debt stands at $13.3 billion, significantly lower than Pfizer’s $62.6 billion following its Seagen acquisition. Additionally, J&J’s net debt/EBITDA ratio of 0.44x is far more favorable than Pfizer's 2x, indicating that Johnson & Johnson is in a much stronger position in terms of managing debt, especially in comparison to Pfizer’s higher leverage. This stability bodes well for JNJ in terms of handling future challenges and maintaining shareholder value.

Dividends and Yield

For income-focused investors, J&J offers a dividend yield of 3.01%, while Pfizer provides a higher yield of 6.51%. However, J&J has a long track record of increasing its dividends, making it an attractive choice for those seeking stable, reliable returns. On the other hand, Pfizer's dividend yield may be considered more attractive for high-income investors, especially with analysts projecting continued dividend growth over the next few years for both companies.

Revenue Composition and Pipeline

The portfolio of products behind J&J and Pfizer plays a crucial role in shaping future growth. In Q4 2024, J&J’s MedTech division, responsible for products in Vision and Cardiovascular franchises, generated $8.19 billion in sales, a 6.7% increase. This represents a more balanced mix of revenue streams compared to Pfizer, which has a more vaccine-heavy portfolio, especially with its Comirnaty COVID-19 vaccine. However, J&J faces challenges with declining sales in some of its blockbuster drugs, like Stelara, and its MedTech portfolio’s long-term prospects depend heavily on patent renewals and market competition.

Pipeline and Acquisition Strategy

Johnson & Johnson’s strategic acquisition of Intra-Cellular Therapies (ITCI) for $14 billion in March 2024 is a significant move aimed at expanding its presence in psychiatric care, specifically in schizophrenia and bipolar disorder markets. The acquisition of ITCI’s Caplyta, a treatment for schizophrenia, provides J&J with a high-potential asset as Caplyta is poised to reach $1 billion in sales by 2025. This aligns with J&J’s ongoing efforts to replenish its aging portfolio. Meanwhile, Pfizer has also been active in acquisitions, but its pipeline lacks the diversity of J&J’s, especially in terms of MedTech and the non-pharma segments.

Patent Expirations and Market Threats

One of J&J’s most significant challenges comes from the expiration of patents for some of its leading drugs. Stelara has already seen some decline, and while the company is attempting to offset these losses with products like Tremfya, there is still considerable revenue pressure in its pharma division. On the other hand, Caplyta offers J&J a more sustainable option in schizophrenia and bipolar depression treatment, with patent protection until 2033. This patent protection gives J&J a competitive edge over rivals, potentially mitigating the impact of Stelara’s patent expiry in the coming years.

Technical Analysis and Market Sentiment

From a technical standpoint, J&J stock is facing some challenges. The price is currently above the second standard deviation band formed from the VWAP, indicating an overbought condition. The RSI is nearing overbought levels at 67.4, and bearish divergences are forming. These signals suggest that J&J stock may be approaching a peak and could experience a correction in the near future. Comparatively, Pfizer has a more favorable technical outlook, with analysts projecting a 20% upside for PFE from its current stock price, while J&J has a much smaller 2.4% upside.

Future Prospects and Growth Drivers

Looking ahead, J&J’s future prospects hinge on several key drivers. The success of its Caplyta acquisition will be crucial in strengthening its position in the psychiatric care market, especially as Stelara faces increasing competition. Additionally, J&J’s pipeline is promising, with ongoing developments in immunology and neurology. However, the company must also manage the risks associated with its generics market and the impending patent expirations.

Final Thoughts: Buy, Sell, or Hold?

Given Johnson & Johnson’s stable financial position, strong dividend history, and strategic acquisitions, it remains a strong hold for conservative investors seeking a balanced portfolio with exposure to both pharma and MedTech. However, from a growth perspective, Pfizer appears to have a slight edge, with more favorable technical indicators and a promising pipeline driven by recent acquisitions. While JNJ remains a solid investment with lower risk, investors looking for higher returns and more dynamic growth could consider Pfizer as a more attractive option at current levels.

For Johnson & Johnson, the stock is fairly valued but might face challenges in the short term due to market conditions and patent expirations. Investors should watch for any significant changes in its acquisitions or pipeline developments that could bolster future earnings. For those invested in JNJ, the long-term outlook remains positive, but near-term volatility could present opportunities to re-enter at a more favorable price.

Decision: Hold NYSE:JNJ.

That's TradingNEWS